The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: -8.00 (-2.63%)
Spread: 4.00 (1.356%)
Open: 292.00
High: 298.00
Low: 292.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed sinks on US FDA drug rejection

Tue, 03rd May 2022 11:29

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Vast Resources PLC, up 50% at 0.51 pence, 12-month range 0.08p-10.00p. The Romania and Zimbabwe-focused miner says revenue more than doubled to USD2.3 million in the first quarter from USD970,465 in the fourth quarter. Reports increase in tons milled and in dry-metric-ton production at the Baita Plai polymetallic mine in Romania.

----------

Eneraqua Technologies PLC, up 10% at 280.00p, up 1.1% from November listing price of 277.00p. The energy and water efficiency services provider wins contract from the Indian state government of Uttarakhand to reduce carbon emissions and improve water efficiency. The northern state has a population of over 10 million people. Contract is worth GBP900,000 from the state's Department of Horticulture will see Eneraqua supply systems to 340 horticultural farms across the state.

----------

AIM - LOSERS

----------

Hutchmed (China) Ltd, down 15% at 208.00p, 12-month range 202.50p-656.00p. The US Food & Drug Administration has rejected the drugmaker's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA said the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
28 Jul 2021 11:33

IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

Read more
28 Jul 2021 10:58

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

Read more
21 Jul 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
16 Jul 2021 11:19

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

Read more
16 Jul 2021 10:55

IN BRIEF: Hutchmed tumor drug qualifies for formal review by EU agency

IN BRIEF: Hutchmed tumor drug qualifies for formal review by EU agency

Read more
13 Jul 2021 15:42

Hutchmed makes first commercial sale of 'Orpathys' in China

(Sharecast News) - Hutchmed China announced the first commercial sale in China of 'Orpathys', or savolitinib, on Tuesday, which is its "oral, potent, and highly-selective" small molecule inhibitor of MET, a receptor tyrosine kinase.

Read more
13 Jul 2021 14:06

TRADING UPDATES: Smiths gets Euros sticker boost; Hotel Chocolat grows

TRADING UPDATES: Smiths gets Euros sticker boost; Hotel Chocolat grows

Read more
6 Jul 2021 20:38

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

Read more
1 Jul 2021 19:26

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

Read more
30 Jun 2021 19:14

TRADING UPDATES: Topps Tiles improves as curbs ease; Bermele makes buy

TRADING UPDATES: Topps Tiles improves as curbs ease; Bermele makes buy

Read more
23 Jun 2021 18:10

IN BRIEF: Hutchmed launches global offering for 104 million shares

IN BRIEF: Hutchmed launches global offering for 104 million shares

Read more
22 Jun 2021 20:16

IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China

IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China

Read more
18 Jun 2021 17:26

IN BRIEF: Hutchmed launches Hong Kong IPO; drug candidate approved

IN BRIEF: Hutchmed launches Hong Kong IPO; drug candidate approved

Read more
18 Jun 2021 08:52

Hutchmed China launches Hong Kong public offering

(Sharecast News) - Hutchmed China announced the launch of its Hong Kong public offering on Friday, as part of its global offering of 104 million new shares, proposing the primary listing of its ordinary shares on the main board of the Hong Kong Stock Exchange under the stock code '13'.

Read more
4 May 2021 20:25

TRADING UPDATES: Cordiant deploys IPO funds; Scotgold gets loan

TRADING UPDATES: Cordiant deploys IPO funds; Scotgold gets loan

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.